431 related articles for article (PubMed ID: 29033244)
1. iASPP Is an Antioxidative Factor and Drives Cancer Growth and Drug Resistance by Competing with Nrf2 for Keap1 Binding.
Ge W; Zhao K; Wang X; Li H; Yu M; He M; Xue X; Zhu Y; Zhang C; Cheng Y; Jiang S; Hu Y
Cancer Cell; 2017 Nov; 32(5):561-573.e6. PubMed ID: 29033244
[TBL] [Abstract][Full Text] [Related]
2. iASPP-Mediated ROS Inhibition Drives 5-Fu Resistance Dependent on Nrf2 Antioxidative Signaling Pathway in Gastric Adenocarcinoma.
Wen L; Yang S; Li P; Chen R; Wang Q; Kaspo B; Fan H; Hu J
Dig Dis Sci; 2020 Oct; 65(10):2873-2883. PubMed ID: 31938994
[TBL] [Abstract][Full Text] [Related]
3. Increases of iASPP-Keap1 interaction mediated by syringin enhance synaptic plasticity and rescue cognitive impairments via stabilizing Nrf2 in Alzheimer's models.
Wang CY; Zhang Q; Xun Z; Yuan L; Li R; Li X; Tian SY; Xin N; Xu Y
Redox Biol; 2020 Sep; 36():101672. PubMed ID: 32828017
[TBL] [Abstract][Full Text] [Related]
4. aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
Tian L; Lu Y; Yang T; Deng Z; Xu L; Yao W; Ma C; Li X; Zhang J; Liu Y; Wang J
Redox Biol; 2019 Apr; 22():101149. PubMed ID: 30822690
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of the Keap1 gene inactivates its function, promotes Nrf2 nuclear accumulation, and is involved in arsenite-induced human keratinocyte transformation.
Wang D; Ma Y; Yang X; Xu X; Zhao Y; Zhu Z; Wang X; Deng H; Li C; Gao F; Tong J; Yamanaka K; An Y
Free Radic Biol Med; 2015 Dec; 89():209-19. PubMed ID: 26409248
[TBL] [Abstract][Full Text] [Related]
6. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
7. RPB5-Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding.
Wan ZH; Jiang TY; Shi YY; Pan YF; Lin YK; Ma YH; Yang C; Feng XF; Huang LF; Kong XN; Ding ZW; Tan YX; Dong LW; Wang HY
Hepatology; 2020 Jun; 71(6):2005-2022. PubMed ID: 31541481
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
9. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.
Habib E; Linher-Melville K; Lin HX; Singh G
Redox Biol; 2015 Aug; 5():33-42. PubMed ID: 25827424
[TBL] [Abstract][Full Text] [Related]
10. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
11. FAM129B, an antioxidative protein, reduces chemosensitivity by competing with Nrf2 for Keap1 binding.
Cheng KC; Lin RJ; Cheng JY; Wang SH; Yu JC; Wu JC; Liang YJ; Hsu HM; Yu J; Yu AL
EBioMedicine; 2019 Jul; 45():25-38. PubMed ID: 31262713
[TBL] [Abstract][Full Text] [Related]
12. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
Wang Q; Ma J; Lu Y; Zhang S; Huang J; Chen J; Bei JX; Yang K; Wu G; Huang K; Chen J; Xu S
Oncogene; 2017 Sep; 36(37):5321-5330. PubMed ID: 28534518
[TBL] [Abstract][Full Text] [Related]
13. A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells.
Li H; Zhang W; Zhao K; Zhao D; Zheng S; Hu Y
J Biol Chem; 2020 Mar; 295(12):4049-4063. PubMed ID: 32005663
[TBL] [Abstract][Full Text] [Related]
14. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2.
Sun Z; Zhang S; Chan JY; Zhang DD
Mol Cell Biol; 2007 Sep; 27(18):6334-49. PubMed ID: 17636022
[TBL] [Abstract][Full Text] [Related]
15. Identification of an adaptor protein that facilitates Nrf2-Keap1 complex formation and modulates antioxidant response.
Zhang Y; Hou Y; Liu C; Li Y; Guo W; Wu JL; Xu D; You X; Pan Y; Chen Y
Free Radic Biol Med; 2016 Aug; 97():38-49. PubMed ID: 27212020
[TBL] [Abstract][Full Text] [Related]
16. Nrf2-Keap1 antioxidant defense and cell survival signaling are upregulated by 17β-estradiol in homocysteine-treated dopaminergic SH-SY5Y cells.
Chen CS; Tseng YT; Hsu YY; Lo YC
Neuroendocrinology; 2013; 97(3):232-41. PubMed ID: 22948038
[TBL] [Abstract][Full Text] [Related]
17. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
[TBL] [Abstract][Full Text] [Related]
18. Directly interact with Keap1 and LPS is involved in the anti-inflammatory mechanisms of (-)-epicatechin-3-gallate in LPS-induced macrophages and endotoxemia.
Chiou YS; Huang Q; Ho CT; Wang YJ; Pan MH
Free Radic Biol Med; 2016 May; 94():1-16. PubMed ID: 26878775
[TBL] [Abstract][Full Text] [Related]
19. The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis.
Zhou XL; Zhu CY; Wu ZG; Guo X; Zou W
Oncogene; 2019 May; 38(21):4028-4046. PubMed ID: 30692632
[TBL] [Abstract][Full Text] [Related]
20. Role of the Keap1-Nrf2 pathway in cancer.
Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
Adv Cancer Res; 2014; 122():281-320. PubMed ID: 24974185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
